SciELO - Scientific Electronic Library Online

vol.63 issue2Validation of three analytical methods for quantification of acetaminophen by UV spectrophotometryLower back pain after iodine-131-6-β-iodomethyl-19-norcholesterol injection: a case report author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Ars Pharmaceutica (Internet)

On-line version ISSN 2340-9894


CARRERA-HUESO, Francisco Javier et al. Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic. Ars Pharm [online]. 2022, vol.63, n.2, pp.166-172.  Epub Apr 25, 2022. ISSN 2340-9894.


The aim of this study was to characterize the use of tocilizumab in a hospital.


Retrospective cohort study including adult SARS-CoV-2 infected inpatients with moderately severe infection (PaO2/FiO2 < 300). ORs for mortality and treatment success were calculated.


The tocilizumab group (n=18), presented 5 days of symptoms vs 7 days in the untreated group (n=71). Minimum PaO2/FiO2 was 147.5 (95%CI: 116.7 to 194.0) vs 255.6 (95%CI: 320.7 to 452.4) (p=0.01).

No significant differences were found between the two groups concerning survival (OR=1.22; 95%CI: 0.38 to 3.92), nor treatment success (OR=0.46; 95%CI: 0.16 to 1.33). After adjusting for age, sex and total corticosteroid dose, OR for success was 0.18 (95%CI: 0.03 to 0.96), while mortality was not significant.


The use of tocilizumab in moderately severe hospitalized patients could decrease the hyperinflammatory state preventing disease progression.

Keywords : Tocilizumab; COVID-19; cohort study.

        · abstract in Spanish     · text in English     · English ( pdf )